Fundz

Illimis secures $42 million in Series B funding to advance GAIA-based Alzheimer’s therapies.

PRIVATEJul 14, 2025

Amount Raised

$42 Million

Round Type

Series B

SeoulBiotechnologyHealth CareTherapeutics

Investors

Dayli PartnersGS VenturesQuad Asset ManagementKorea Development BankWoori Venture Partners

Description

Illimis has successfully raised $42 million in a Series B funding round to advance its efforts in developing therapeutics for Alzheimer’s disease. The funding will support Illimis in furthering research and development of its GAIA-based therapies. This investment marks a significant step for the company as it works toward creating innovative solutions for Alzheimer's disease.

Who to call at Illimis Therapeutics, and when

A new round usually means Illimis Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Illimis Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Illimis Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Illimis Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Illimis Therapeutics

Location

Seoul, Seoul, South Korea

About

Illimis Therapeutics is a biotechnology company focused on developing therapeutics for CNS and immune diseases using its innovative GAIA platform. The company aims to create next-generation treatment options for neuro-immune diseases, addressing high unmet medical needs. Illimis actively engages in partnerships with global pharmaceutical companies and research institutions to enhance its drug development capabilities. It has secured various funding and collaborations to advance its research and development efforts.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Illimis Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Illimis Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Illimis Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.